Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Sadif Analytics (Premium)
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck KGaA's Stimuvax Misses Primary Endpoint In Phase III Trial-DJ


Wednesday, 19 Dec 2012 01:44am EST 

Dow Jones reported that Merck KGaA said a Phase III trial of Stimuvax on patients with non small cell lung cancer didn't meet the primary endpoint, or a significant improvement in overall survival. Stimuvax refers to Merck's product L-BLP25. Despite not meeting the primary endpoint, notable treatment effects were seen for L-BLP25 in certain subgroups. Further analysis is planned in the coming weeks to explore the potential benefit-risk profile of L-BLP25 in certain populations. Merck KGaA has an exclusive licensing agreement with U.S.-based Oncothyreon Inc. (ONTY) for Stimuvax. 

Company Quote

63.0
-1.9 -2.93%
15 Aug 2014